Ann: Appendix 3Y-Dr Geoffrey Brooke, page-26

I and others on here are consumately acquainted with the timescales involved in bio-tech investments Pledge, thanks for your concerns over me or others being unaware of CYP's as yet uncompleted pathway to actual commercial success. Why I personally have been not been invested in both MSB and CYP for the vast majority of their listed history since 2004 and 2007 respectively, along with the share prices.

Its about the entry levels Pledge and the trading prices of CYP is now well above my buy average, and MSB for that matter, whilst both are a long way from the eventual commercial success we are all ultimately investing in. For abnormal returns on both investments I don't personally (nor many others reading) need either to be actually in market selling treatments commercially, just the market to be aware they soon will be and forward valued accordingly.

(I can almost hear you laud MSB's recent and hopefully pending progress with the FDA over CYP holders - suits me as an investor in both (and arguably CYP investors who are not invested in MSB) - when its only a few years ahead of CYP which itself might have similarly progressed levels to that of MSB i.e. it too 20 years after its IPO might finally be sniffing at approvals )